Advertisement

Nasopharyngeal carcinoma: relationship to Epstein-Barr virus and treatment with interferon

  • Joseph M. Connors
  • Charlotte Jacobs
Part of the Cancer Treatment and Research book series (CTAR, volume 32)

Abstract

Nasopharyngeal carcinoma Nasopharyngeal carcinoma (NPC) is a unique epithelial neoplasm which accounts for 85% of malignancies of the nasopharynx [1]. It has several special characteristics, including its geographical and ethnic distribution and its relationship to Epstein-Barr virus (EBV), the causative agent of infectious mononucleosis. Although relatively rare in the overall population of North America with an incidence of 4 per million, it is 25 times more common in Chinese Americans [1] and also has an increased frequency in Alaskan natives [2]. Worldwide it is an important tumor because of its wide distribution and high incidence in certain areas such as Southern China [3], North Africa [4, 5] and Southeast Asia [5]. It occurs about twice as often in males and reaches its peak incidence in the fourth through sixth decades [1].

Keywords

Herpes Zoster Nasopharyngeal Carcinoma Mycosis Fungoides Hairy Cell Leukemia Infectious Mononucleosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Levine, P.H., Connelly, R.R., Easton, J.M. 1980. Demographic patterns for nasopharyngeal carcinoma in the United States. Int. J. Cancer 26: 741–748.PubMedCrossRefGoogle Scholar
  2. 2.
    Lanier, A. 1977. Survey of cancer incidence in Alaskan natives. Nat. Cancer Inst. Monog. 47: 87–88.Google Scholar
  3. 3.
    Clifford, P. 1970. A review on the epidemiology of nasopharyngeal carcinoma. Int. J. Cancer 5: 287–309.PubMedCrossRefGoogle Scholar
  4. 4.
    Malik, M.O.A., Banatvala, J., Hutt, M.S.R., Abu-Sim, A.Y., Hidaytallah, A., El-Hadi, A.E. 1979. Epstein-Barr virus antibodies in Sudanese patients with nasopharyngeal carcinoma: a preliminary report. J.N.C.I. 62: 221–224.Google Scholar
  5. 5.
    Muir, C.S. 1971. Nasopharyngeal carcinoma in non-Chinese populations with special reference to southeast Asia and Africa. Int. J. Cancer 8: 351–363.PubMedGoogle Scholar
  6. 6.
    Henderson, B.E., Louie, E., Jing, S.J., Buell, P., Gardner, M.E. 1976. Risk factors associated with nasopharyngeal carcinoma. N. Engl. J. Med. 295: 1101–1106.PubMedCrossRefGoogle Scholar
  7. 7.
    Fedder, M., Gonzalez, M.F., 1985. Nasopharyngeal carcinoma: brief review. A. J. Med. 79: 365–369.CrossRefGoogle Scholar
  8. 8.
    Baker, S.R., Wolfe, R.A. 1982. Prognostic factors of nasopharyngeal malignancy. Cancer 42: 163–169.CrossRefGoogle Scholar
  9. 9.
    Mesic, J.B., Fletcher, G.H., Goepfert, H. 1981. Megavoltage irradiation of epithelial tumors of the nasopharynx. Int. J. Radiat. Oncol. Biol. Ohys. 7: 447–453.CrossRefGoogle Scholar
  10. 10.
    Hoppe, R.T., Goffinet, D.R., Bagshaw, M.A. 1946. Carcinoma of the nasopharynx. Cancer 37: 2605–2612.CrossRefGoogle Scholar
  11. 11.
    Decker, D.A., Drelichman, A., Al-Sarraf, M., Crissman, J., Reed, M.L. 1983. Chemotherapy for nasopharyngeal carcinoma. Cancer 52: 602–605.PubMedCrossRefGoogle Scholar
  12. 12.
    Heule, W., Heule, G., Lennette, E.T. 1979. The Epstein-Barr virus. Sci. Am. 241: 48–49.CrossRefGoogle Scholar
  13. 13.
    Huang, D.P., Ho, H.C., Henle, W., Henle, G., Saw, D., Lui, M. 1970. Presence of EBNA in nasopharyngeal carcinoma and control patient tissues related to EBV serology. Int. J. Cancer 22: 266–274.CrossRefGoogle Scholar
  14. 14.
    Lanier, A., Bender, T., Talbot, M. et al. 1980. Epstein-Barr virus DNA in tumor tissue from native Alaskan patients with nasopharyngeal carcinoma. Lancet 2: 1095.Google Scholar
  15. 15.
    Lanier, A.P., Bornkamm, G.W., Henle, W. et al. 1981. Association of Epstein-Barr virus with nasopharyngeal carcinoma in Alaskan native patients: serum antibodies and tissue EBNA and DNA. Int. J. Cancer 28: 301–305.PubMedCrossRefGoogle Scholar
  16. 16.
    Ringborn, U., Henle, W., Henle, G. et al. 1983. Epstein-Barr virus specific sérodiagnostic tests in carcinomas of the head and neck. Cancer 52: 1237–1243.CrossRefGoogle Scholar
  17. 17.
    Andersson-Anvret, M., Forsby, N., Klein, G., Henle, W., Biorklund, A. 1979. Relationship between the Epstein-Barr virus genome and nasopharyngeal carcinoma in caucasian patients. Int. J. Cancer 23: 762–767.PubMedCrossRefGoogle Scholar
  18. 18.
    Desgranges, C., Pi, G.H., Bornkamm, G.W., Legrand, C., Zeng, Y., De-The, G. 1983. Presence of EBV-DNA sequences in nasopharyngeal cells of individuals without I-VCA antibodies. Int. J. Cancer 32: 543–545.PubMedCrossRefGoogle Scholar
  19. 19.
    Tumper, P.A., Epstein, M.A., Giovanella, B.C., Finerty, D. 1977. Isolation of infectious EB virus from the epithelial tumor cells of nasopharyngeal carcinoma. Int. J. Cancer 20: 655–662.CrossRefGoogle Scholar
  20. 20.
    Henle, W., Ho, J.H.C., Henle, G, Chau, J.W.C., Kwan, H.C. 1977. Nasopharyngeal carcinoma: significance of changes in Epstein-Barr virus related antibody patterns following therapy. Int. J. Cancer 20: 663–672.PubMedCrossRefGoogle Scholar
  21. 21.
    Moss, D.J., Chan, S.H., Burrows, S.R. et al. 1983. Epstein-Barr virus specific T-cell response in nasopharyngeal carcinoma patients. Int. J. Cancer 32: 301–305.PubMedCrossRefGoogle Scholar
  22. 22.
    Ho, H.L., Kwan, H.C., Wu, P., Chan, S.K., Ng, M.H., Saw, D. 1978. Epstein-Barr antibodies in suspected nasopharyngeal carcinoma. Lancet 2: 1094–1095.PubMedCrossRefGoogle Scholar
  23. 23.
    Ho, H.C., Ng, M.H., Kwan, H.C. 1978. Factors affecting serum I antibody to Epstein-Barr viral capsid antigens in nasopharyngeal carcinoma. Br. J. Cancer 37: 356–362.PubMedCrossRefGoogle Scholar
  24. 24.
    Desgranges, C., De-The, G. 1979. Epstein-Barr virus specific I serum antibodies in nasopharyngeal and other respiratory carcinomas. Int. J. Cancer 24: 555–559.PubMedCrossRefGoogle Scholar
  25. 25.
    Naegele, R.F., Champion, J., Murphy, D., Henle, G., Henle, W. 1982. Nasopharyngeal carcinoma in American children: Epstein-Barr virus specific antibody titers and prognosis. Int. J. Cancer 29: 209–212.PubMedCrossRefGoogle Scholar
  26. 26.
    Tamada, A., Makimoto, K., Yamabe, H. et al. 1984. Titers of Epstein-Barr virus related antibodies in nasopharyngeal carcinoma in Japan. Cancer 53: 430–440.PubMedCrossRefGoogle Scholar
  27. 27.
    Henle, G., Henle, W. 1976. Epstein-Barr virus specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int. J. Cancer 17: 1–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Pearson, G.R., Weiland, L.H., Neel, H.B. et al. 1983. Application of Epstein-Barr virus (EBV) serology to the diagnosis of North American nasopharyngeal carcinoma. Cancer 51: 260–268.PubMedCrossRefGoogle Scholar
  29. 29.
    Coates, H.L., Pearson, G.R., Neel, H.B., Weiland, L.H., Devine, K.D. 1978. An immunologic basis for detection of occult primary malignancies of the head and neck. Cancer 41: 912–918.PubMedCrossRefGoogle Scholar
  30. 30.
    Ho, H.C., Ng, M.H., Kwan, H.C., Chau, J.W.C. 1976. Epstein-Barr virus specific IgA and IgG serum antibodies in nasopharyngeal carcinoma. Br. J. Cancer 34: 655–660.PubMedCrossRefGoogle Scholar
  31. 31.
    Zeng, Y., Zhang, L.G., Li, H.Y., et al. 1982. Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. Int. J. Cancer 39: 139–141.CrossRefGoogle Scholar
  32. 32.
    Lanier, A.P., Henle, W., Bender, T.R., Henle, G., Talbot, M. 1980. Epstein-Barr virus specific antibody titers in seven Alaskan natives before and after diagnosis of nasopharyngeal carcinoma. Int. J. Cancer 26: 133–137.PubMedCrossRefGoogle Scholar
  33. 33.
    Ho, H.C., Kwan, H.C., Ng, M.H., De-The, G. 1978. Serum I antibodies to Epstein-Barr virus capsid antigen preceding symptoms of nasopharyngeal carcinoma. Lancet 1: 436.PubMedCrossRefGoogle Scholar
  34. 34.
    Tan, R.S., Cheng, Y.C., Naegele, R.F., Henle, W., Glaser, R., Champion, J. 1982. Antibody responses to Epstein-Barr virus specific DNase in relation to the prognosis of juvenile patients with nasopharyngeal carcinoma. Int. J. Cancer 30: 561–565.PubMedCrossRefGoogle Scholar
  35. 35.
    Desgranges, C., Li, J.Y., De-The, G. 1977. EBV specific secretory IgA in saliva of NPC patients. Presence of secretory piece in epithelial malignant cells. Int. J. Cancer 20: 881–886.PubMedCrossRefGoogle Scholar
  36. 36.
    Ho, H.C., Kwan, H.C., Poon, Y.F., Tse, K.C., Ng, L.H. 1978. Epstein-Barr virus infection in staff treating patients with nasopharyngeal carcinoma. Lancet 1: 710–711.PubMedCrossRefGoogle Scholar
  37. 37.
    Pearson, G.R., Neel, H.B., Weiland, L.H. et al. Antibody dependent cellular cytotoxicity and disease course in North American patients with nasopharyngeal carcinoma: a prospective study. Int. J. Cancer 33: 777–782.Google Scholar
  38. 38.
    Chan, S.H., Levin, P.H., De-The, G.B. et al. 1979. A comparison of the prognostic value of antibody dependent lymphocyte cytotoxicity and other EBV antibody assays in Chinese patients with nasopharyngeal carcinoma. Int. J. Cancer 23: 181–185.PubMedCrossRefGoogle Scholar
  39. 39.
    Pearson, G.R., Johansson, B., Klein, G. 1978. Antibody dependent cellular cytotoxicity against Epstein-Barr virus associated antigens in African patients with nasopharyngeal carcinoma. Int. J. Cancer 22: 120–125.PubMedCrossRefGoogle Scholar
  40. 40.
    Greenberg, H.B., Pollard, R.B., Lutwick, L.I., Gregory, P.B., Robinson, W.S., Merigan, T.C. 1976. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N. Engl. J. Med. 295: 517–522.PubMedCrossRefGoogle Scholar
  41. 41.
    Oxman, M.W. 1973. Interferon, tumors and tumor viruses. In: Interferon and Interferon Inducers (N.B. Finter, ed.). American Elsevier Publishing Co., New York, pp. 391–479.Google Scholar
  42. 42.
    Arvin, A.M., Kushner, J.H., Feldman, S., Baehner, R.L., Hammond, D., Merigan, T.C. 1982. Human leukocyte interferon for the treatment of varicella in children with cancer. N. Engl. J. Med. 306: 761–765.PubMedCrossRefGoogle Scholar
  43. 43.
    Merigen, T.C., Rand, K.H., Pollard, R.B. et al. 1978. Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. N. Engl. J. Med. 298: 981–987.CrossRefGoogle Scholar
  44. 44.
    Rasmussen, L., Farley, L.B. 1975. Inhibition of herpesvirus replication by human interferon. Infect. Immun. 12: 104–108.PubMedGoogle Scholar
  45. 45.
    Cheeseman, S.H., Henle, W., Rubin, R. 1980. Epstein-Barr virus infection in renal transplant recipients. Ann. Intern. Med. 93: 39–42.PubMedGoogle Scholar
  46. 46.
    Borden, E.C.. 1979. Interferons: rationale for clinical trials in neoplastic disease. Ann. Intern. Med. 91: 472–479.PubMedGoogle Scholar
  47. 47.
    Kirkwood, J.M., Ernstoff, M.S. 1984. Interferons in the treatment of human cancer. J. Clin. Oncol. 2: 336–352.PubMedGoogle Scholar
  48. 48.
    Krasic, J., Kirkmajer, V., Knezevic, M. et al. 1981. Influence of human leukocyte interferon on squamous cell carcinoma of the uterine cervix. Clinical, histological and histochemical observations III. J. Cancer Res. Clin. Oncol. 101: 309–315.CrossRefGoogle Scholar
  49. 49.
    Haglund, S., Lundquist, P.G., Cantell, K. et al. 1981. Interferon therapy in juvenile laryngeal papillomatosis. Arch. Otolaryngol. 107: 327–332.PubMedGoogle Scholar
  50. 50.
    Treuner, J., Niethammer, D., Dannecker, G., Hogmann, R., Neef, V., Hofschneider, P.H. 1980. Successful treatment of nasopharyngeal carcinoma with interferon. Lancet 1: 817–818.PubMedCrossRefGoogle Scholar
  51. 51.
    Vallbracht, A., Treuner, J., Flehmig, K., Joester, E., Biethammer, D. 1981. Interferon neutralizing antibodies in a patient treated with human fibroblast interferon. Nature 289: 496–497.PubMedCrossRefGoogle Scholar
  52. 52.
    Vallbracht A., Treuner, J., Manncke, K.H., Niethammer, D., 1982. Autoantibodies against human beta interferon following treatment with interferon. J. Interferon Res. 2: 107–110.PubMedCrossRefGoogle Scholar
  53. 53.
    Connors, J.M., Andiman, W.A., Howarth, C.B. et al. 1985. Treatment of nasopharyngeal carcinoma with human leukocyte interferon. J. Clin. Oncol. 3: 813–817.PubMedGoogle Scholar
  54. 54.
    Matheson, D.S., Tan, Y.H., Green, B., McPherson, T.A. 1983. Effect of fibroblast derived interferon administration on immune responsiveness in a patient with nasopharyngeal carcinoma. J. Interferon Res. 3: 437–441.PubMedCrossRefGoogle Scholar
  55. 55.
    Treuner, J., Niethammer, D., 1984. Behandlung des nasopharynxkarzinoms mit Interferon. Strahlentherapie 160, special issue 78: 184–187.Google Scholar
  56. 56.
    Mertens, R., Karstens, J.H., Ammon, J., Classen, H.W., Mittermayer, C. 1984. Bisherige Erfahrungen der Interferontherapie an 7 Patienten mit nasopharynxkarzinom. Strahlentherapie 160, special issue 78: 188–193.Google Scholar
  57. 57.
    Furukawa, M., 1984. Treatment and clinical results of nasopharyngeal carcinoma (NPC) with interferon (IFN-beta) and its effects on Epstein-Barr virus (EBV) serology. Otolaryngology (Tokyo) 56: 899–903.Google Scholar
  58. 58.
    Jenkin, R.D., Anderson, J.R., Jereb, B. et al. 1981. Nasopharyngeal carcinoma - a retrospective review of patients less than thirty years of age: A report from Childrens Cancer Study Group. Cancer 47: 360–366.PubMedCrossRefGoogle Scholar
  59. 59.
    Strauch, B., Siegel, N., Andrews, L., Miller, G. 1974. Oropharyngeal excretion of Epstein-Barr virus by renal transplant recipients and other patients treated with immunosuppressive drugs. Lancet 1: 234–237.PubMedCrossRefGoogle Scholar
  60. 60.
    Chang, R.S., Lewis, J.P., Reynolds, R.D. et al., 1978. Oropharyngeal excretion of Epstein-Barr virus by patients with lymphoproliferative disorders and by recipients of renal homografts. Ann. Intern. Med. 88: 34–40.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1987

Authors and Affiliations

  • Joseph M. Connors
  • Charlotte Jacobs

There are no affiliations available

Personalised recommendations